Copyright
©The Author(s) 2019.
World J Clin Oncol. Mar 24, 2019; 10(3): 136-148
Published online Mar 24, 2019. doi: 10.5306/wjco.v10.i3.136
Published online Mar 24, 2019. doi: 10.5306/wjco.v10.i3.136
Figure 3 Estimated survival function of head and neck squamous cell carcinoma patients for fibroblast growth factor receptor 4 genotype and expression.
A: Wildtype fibroblast growth factor receptor 4 (FGFR4) Gly388 and mutant FGFR4 Arg388 are compared. The P-value reported is the result of the Log-rank test for comparison of survivals; B: Weak expression vs high expression are shown within the first 24 mo of survival study.
- Citation: Wimmer E, Ihrler S, Gires O, Streit S, Issing W, Bergmann C. Fibroblast growth factor receptor 4 single nucleotide polymorphism Gly388Arg in head and neck carcinomas. World J Clin Oncol 2019; 10(3): 136-148
- URL: https://www.wjgnet.com/2218-4333/full/v10/i3/136.htm
- DOI: https://dx.doi.org/10.5306/wjco.v10.i3.136